Respiratory medicine
-
Respiratory medicine · Jul 2019
Meta AnalysisEffect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
Patients with severe asthma can present with overlapping eosinophilic and allergic phenotypes, which makes it challenging when deciding which biologic therapy is most appropriate to reduce exacerbations and help achieve asthma control. ⋯ This analysis indicated that mepolizumab 100 mg SC has clinical benefit in patients with blood eosinophil counts ≥150 cells/μL (or history of ≥300 cells/μL), regardless of allergic characteristics or omalizumab eligibility.